The IMPAACT HIV Treatment Scientific Committee aims to evaluate the pharmacokinetics (PK), safety, and drug interactions of new and existing antiretroviral (ARV) agents and formulations leading to optimal dosing and licensing for HIV-infected infants, children, adolescents, and pregnant/postpartum women. Despite licensure of more than 30 ARVs in adults, most of the new ARVs have not been evaluated for PK, safety and dosing in pregnant women, children, and especially newborns and infants. Priorities include evaluation of PK properties of ARVs and related drugs during pregnancy and postpartum as well as PK and safety of ARV and related drugs for infants, children, and adolescents.
Committee ContactsChair: Elaine Abrams
Vice-Chair: Ted Ruel
Operations Center: Sarah Bradford and Katie McCarthy
Presentations2016 IMPAACT Annual Meeting Treatment Committee presentations
Studies Within This Research Area